Edition:
United States

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

33.28USD
20 Oct 2017
Change (% chg)

$0.13 (+0.39%)
Prev Close
$33.15
Open
$33.22
Day's High
$33.37
Day's Low
$33.15
Volume
1,311,558
Avg. Vol
2,314,322
52-wk High
$34.00
52-wk Low
$17.61

Select another date:

Tue, Oct 3 2017

Senvest Management shorting drug stocks Insys, Akorn, Fresenius

TEL AVIV, Oct 3 New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday,

BRIEF-Fresenius SE says Akorn shareholders approved merger

* At yesterday's special meeting, shareholders of Akorn, Inc., have approved merger agreement with fresenius kabi, with 83.9 percent of outstanding shares being voted in favour of transaction. Source text for Eikon: Further company coverage:

BRIEF-Akorn shareholders vote to approve merger agreement with Fresenius Kabi

* Akorn shareholders vote to approve merger agreement with Fresenius Kabi

Fresenius picks up M&A pace with Akorn, Merck KGaA deals

FRANKFURT German healthcare group Fresenius SE & Co KGaA has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany's Merck KGaA.

UPDATE 2-Fresenius picks up M&A pace with Akorn, Merck KGaA deals

* Fresenius shares up almost 1 percent (Adds advisers, shares, background, CEO, analyst comments)

BRIEF-Akorn deal to pay Fresenius Kabi AG termination fee of $129 mln under specified circumstances

* Akorn - deal with Fresenius Kabi provides under specified circumstances, co to be required to pay Fresenius Kabi AG termination fee of $129 million Source text: (http://bit.ly/2oEMWQV) Further company coverage:

Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals

FRANKFURT, April 24 Acquisitive German healthcare conglomerate Fresenius SE & Co KGaA revved up its deals pace by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros), and in a separate deal, the biosimilars unit of German peer Merck KGaA .

Exclusive: Fresenius nears deal to acquire Akorn - sources

German healthcare conglomerate Fresenius SE & Co KGaA is close to acquiring generic drugmaker Akorn Inc in an all-cash deal valuing the company at more than $4 billion, people familiar with the matter said on Monday.

Select another date: